Clinical trial
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
NCT00269113 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00269113 |
|---|---|
| Title | A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma |
| Official title | A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab [MabThera/Rituxan], Standard chemotherapy |
| Enrollment | 360 |
| Start date | Sep 1, 1998 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Dec 23, 2005 |
| Last update posted | Jul 23, 2015 |
| Countries | Germany |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: